BBNX BETA BIONICS

Beta Bionics to Present at the Bank of America Securities Health Care Conference

Beta Bionics to Present at the Bank of America Securities Health Care Conference

IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at 12:35 pm Eastern Time (9:35 am Pacific Time).

A live audio webcast of the presentation will be available on the Company’s website in the “Investors—Events & Presentations” section at , and will be archived there for future replay following the event.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit .

Investor Relations:

Blake Beber

Head of Investor Relations

Media and Public Relations:

Karen Hynes

Vice President of Marketing

Source: Beta Bionics, Inc.



EN
01/05/2025

Underlying

BBNXBETA BIONICS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BETA BIONICS

 PRESS RELEASE
Free
BBNX BETA BIONICS

Beta Bionics to Present at the Bank of America Securities Health Care ...

Beta Bionics to Present at the Bank of America Securities Health Care Conference IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at 12:35 pm Eastern Time (9:35 am Pacific Time). A live audio webcast of the presentation will be available on the Company’s website in the “Investors—Events & Presentations” section at , and will be archive...

May 1, 2025 1 EN
 PRESS RELEASE
Free
BBNX BETA BIONICS

Beta Bionics to Announce First Quarter 2025 Financial Results on May 6...

Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025 IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2025 financial results after the financial markets close on Tuesday, May 6, 2025. In connection with the release, management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the C...

April 16, 2025 1 EN
 PRESS RELEASE
Free
BBNX BETA BIONICS

Beta Bionics to Host Investor Event on June 22, 2025

Beta Bionics to Host Investor Event on June 22, 2025 IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it will host an investor event on Sunday, June 22, 2025, in conjunction with the 85th Scientific Sessions of the American Diabetes Association (ADA) taking place June 20-23, 2025, in Chicago, IL. The event will begin at 7:00 am Central Time (8:00 am Eastern Time) and conclude at approximately 8:30 am Central Time (9:30 am Eastern Time)...

April 9, 2025 1 EN
 PRESS RELEASE
Free
BBNX BETA BIONICS

Beta Bionics Announces Board Appointment of Gerard Michel

Beta Bionics Announces Board Appointment of Gerard Michel IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (Nasdaq: DCTH), a commercial-stage interventional oncology company. “We are excited to welcome Gerard to the Beta Bionics Board,” said Sean Saint, President and Chief Executive Offic...

March 27, 2025 1 EN
 PRESS RELEASE
Free
BBNX BETA BIONICS

Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Res...

Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025 IRVINE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2024 and introduced its annual guidance for the year ending December 31, 2025. Fourth Quarter 2024 Financial Highlights & Key Metrics Net sales of $20.4 million, up 145% compared to $8.4 million in the fourth quarter of...

March 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch